Alogliptin etkileşimleri

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (Flukonazol etiketi, İlaç etkileşimleri)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (Glipizid ve metformin etiketi, Kontrendikasyonlar)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (Hidroksiklorokin etiketi, Uyarılar ve önlemler)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (Klorokin etiketi, Uyarılar)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (Siprofloksasin etiketi, İlaç etkileşimleri)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (Abirateron etiketi, Uyarılar ve önlemler)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (Amlodipin ve benazepril etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (Asitretin etiketi, İlaç etkileşimleri)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Atazanavir etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (Benazepril etiketi, İlaç etkileşimleri)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (Benazepril ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Brimonidin ve timolol etiketi, Uyarılar ve önlemler)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (Butalbital, aspirin ve kafein etiketi, İlaç etkileşimleri)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

Caution should be exercised when used with antidiabetic drugs. (Danazol etiketi, İlaç etkileşimleri)

…Coadministered Drug (Dose Regimen) * Dapagliflozin (Dose Regimen) * Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC † No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10… (Dapagliflozin etiketi, İlaç etkileşimleri)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (Darunavir etiketi, Uyarılar ve önlemler)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Darunavir ve kobisistat etiketi, Uyarılar ve önlemler)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (Deksametazon etiketi, Uyarılar ve önlemler)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Dorzolamid ve timolol etiketi, Uyarılar ve önlemler)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (Eksenatid etiketi, Uyarılar ve önlemler)

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. (Enalapril ve hidroklorotiyazid etiketi, Önlemler)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (Fludrokortizon etiketi, İlaç etkileşimleri)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (Fluoksetin etiketi, Uyarılar ve önlemler)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fosamprenavir etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (Hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (Hidrokortizon etiketi, İlaç etkileşimleri)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (İrbesartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (İtrakonazol etiketi, İlaç etkileşimleri)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (Kanagliflozin etiketi, İlaç etkileşimleri)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (Kandesartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (Kapesitabin etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (Ketokonazol etiketi, İlaç etkileşimleri)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (Klaritromisin etiketi, Uyarılar ve önlemler)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (Klorotiyazid etiketi, İlaç etkileşimleri)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotid etiketi, Uyarılar ve önlemler)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Levofloksasin etiketi, Uyarılar ve önlemler)

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (Levotiroksin etiketi, Uyarılar ve önlemler)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Levotiroksin ve liyotironin etiketi, İlaç etkileşimleri)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (Linezolid etiketi, Uyarılar ve önlemler)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (Lisinopril etiketi, İlaç etkileşimleri)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Lisinopril ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

• Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (Liyotironin etiketi, Uyarılar ve önlemler)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Lopinavir ve ritonavir etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (Losartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Metilprednizolon etiketi, İlaç etkileşimleri)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (Metolazon etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic agents Carefully monitor blood glucose. (Moksifloksasin etiketi, İlaç etkileşimleri)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Nadolol etiketi, Uyarılar)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Dipeptidyl peptidase 4 (DPP4) inhibitors saxagliptin ↑ saxagliptin Dosage adjustment of saxagliptin is recommended. (Nirmatrelvir ve ritonavir etiketi, İlaç etkileşimleri)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Ofloksasin etiketi, Uyarılar)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Oktreotid etiketi, Uyarılar ve önlemler)

• Antidiabetic drugs: Dosage adjustment may be required. (Olmesartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (Olmesartan, amlodipin ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (Orlistat etiketi, Uyarılar ve önlemler)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Pindolol etiketi, Uyarılar)

Congestive Heart Failure ACTOS, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. (Pioglitazon etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Congestive Heart Failure Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when pioglitazone is used in combination with insulin. (Pioglitazon ve metformin etiketi, Uyarılar ve önlemler)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Prednizolon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (Pregabalin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (Rifampisin etiketi, İlaç etkileşimleri)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (Rifapentin etiketi, İlaç etkileşimleri)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Ritonavir etiketi, Uyarılar ve önlemler)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (Salsalat etiketi, İlaç etkileşimleri)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin etiketi, Uyarılar ve önlemler)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (Sotalol etiketi, İlaç etkileşimleri)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (Spironolakton ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib etiketi, Uyarılar ve önlemler)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (Sülfametoksazol ve trimetoprim etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (Telmisartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus etiketi, Uyarılar ve önlemler)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Timolol etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Alogliptin etiketi, Uyarılar ve önlemler)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (Trandolapril etiketi, İlaç etkileşimleri)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (Tranilsipromin etiketi, Uyarılar ve önlemler)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Triamsinolon etiketi, İlaç etkileşimleri)

Dyrenium (triamterene) may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (Triamteren etiketi, İlaç etkileşimleri)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (Triamteren ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (Valsartan ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (Vorikonazol etiketi, İlaç etkileşimleri)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (Bupropion etiketi, Uyarılar ve önlemler)

Antidiabetic drug requirements (i.e., insulin) may be altered. (Dietilpropion etiketi, İlaç etkileşimleri)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (Fendimetrazin etiketi, İlaç etkileşimleri)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Klozapin etiketi, Uyarılar ve önlemler)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (Lovastatin etiketi, İlaç etkileşimleri)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (Mikonazol etiketi, İlaç etkileşimleri)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (Moeksipril etiketi, İlaç etkileşimleri)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (Nifedipin etiketi, Önlemler)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Sülfadiazin etiketi, İlaç etkileşimleri)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (Tolmetin etiketi, İlaç etkileşimleri)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Ziprasidon etiketi, Uyarılar ve önlemler)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (Sulindak etiketi, İlaç etkileşimleri)